Literature DB >> 10391860

Similar humoral and cellular immunological reactivities to human herpesvirus 6 in patients with multiple sclerosis and controls.

M Enbom1, F Z Wang, S Fredrikson, C Martin, H Dahl, A Linde.   

Abstract

Several studies have suggested an association between human herpesvirus 6 (HHV-6) and multiple sclerosis (MS). We have previously studied intrathecal production of antibody to lymphotropic herpesviruses in MS patients and the presence of human herpesvirus 1 to 7 DNAs in cerebrospinal fluid (CSF). In the present study anti-HHV-6 immunoglobulin M (IgM) in serum and anti-HHV-6 IgG subclasses in serum and CSF were examined and the lymphoproliferative response to HHV-6 was analyzed. The PCR examination was refined by purifying DNA from CSF and retesting the samples for HHV-6 DNA. There were no statistically significant differences between the groups concerning IgM positivity, distribution of IgG subclasses, or lymphoproliferative response to HHV-6. The purification of DNA increased the number of PCR-positive samples from 0 of 71 to 4 of 68. The study does not give additional support to the possibility that HHV-6 is a common cause of MS, but a role for the virus in a subset of patients cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10391860      PMCID: PMC95725          DOI: 10.1128/CDLI.6.4.545-549.1999

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  21 in total

1.  Lymphoproliferative responses to human herpesvirus-6 variant A and variant B in healthy adults.

Authors:  F Z Wang; H Dahl; P Ljungman; A Linde
Journal:  J Med Virol       Date:  1999-02       Impact factor: 2.327

2.  Lymphocyte proliferation and IgG production with herpesvirus antigens in solid phase.

Authors:  P Ljungman; B Wahren; V A Sundqvist
Journal:  J Virol Methods       Date:  1985-12       Impact factor: 2.014

3.  Identification of proteins specific for human herpesvirus 6-infected human T cells.

Authors:  N Balachandran; R E Amelse; W W Zhou; C K Chang
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

4.  Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infections.

Authors:  A Linde; J Andersson; G Lundgren; B Wahren
Journal:  J Med Virol       Date:  1987-02       Impact factor: 2.327

5.  An enzyme-linked immunosorbent assay for IgG antibodies to human herpes virus 6.

Authors:  H Dahl; A Linde; V A Sundqvist; B Wahren
Journal:  J Virol Methods       Date:  1990-09       Impact factor: 2.014

6.  Antiviral IgM and IgG subclasses in varicella zoster associated neurological syndromes.

Authors:  T Mathiesen; A Linde; E Olding-Stenkvist; B Wahren
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-05       Impact factor: 10.154

7.  Human herpesvirus 6 and multiple sclerosis: survey of anti-HHV-6 antibodies by immunofluorescence analysis and of viral sequences by polymerase chain reaction.

Authors:  P Sola; E Merelli; R Marasca; M Poggi; M Luppi; M Montorsi; G Torelli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-08       Impact factor: 10.154

8.  Possible association of herpes simplex virus infection with demyelinating disease.

Authors:  A Vahlne; S Edström; P Hanner; O Andersen; B Svennerholm; E Lycke
Journal:  Scand J Infect Dis Suppl       Date:  1985

9.  Infrequent detection of human herpesvirus 6 DNA in peripheral blood mononuclear cells from multiple sclerosis patients.

Authors:  M Mayne; J Krishnan; L Metz; A Nath; A Auty; B M Sahai; C Power
Journal:  Ann Neurol       Date:  1998-09       Impact factor: 10.422

Review 10.  Epidemiologic evidence for multiple sclerosis as an infection.

Authors:  J F Kurtzke
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

View more
  16 in total

Review 1.  Human herpesvirus 6 infection as a trigger of multiple sclerosis.

Authors:  Konstantine I Voumvourakis; Dimitrios K Kitsos; Sotirios Tsiodras; George Petrikkos; Eleftherios Stamboulis
Journal:  Mayo Clin Proc       Date:  2010-10-06       Impact factor: 7.616

2.  Detection of antibodies directed against human herpesvirus 6 U94/REP in sera of patients affected by multiple sclerosis.

Authors:  Elisabetta Caselli; Michela Boni; Arianna Bracci; Antonella Rotola; Claudio Cermelli; Massimiliano Castellazzi; Dario Di Luca; Enzo Cassai
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

Review 3.  Update on human herpesvirus 6 biology, clinical features, and therapy.

Authors:  Leen De Bolle; Lieve Naesens; Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 4.  Insights into the immunopathogenesis of multiple sclerosis.

Authors:  Niels Hellings; Jef Raus; Piet Stinissen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

5.  Isolation and growth of a cytopathic agent from multiple sclerosis brain tissue.

Authors:  Anthony R White; Nichole S Dutton; Robert D Cook
Journal:  J Neurovirol       Date:  2002-04       Impact factor: 2.643

6.  Human herpesvirus type 6 indirectly enhances oligodendrocyte cell death.

Authors:  Hong Kong; Quinton Baerbig; Laine Duncan; Nick Shepel; Michael Mayne
Journal:  J Neurovirol       Date:  2003-10       Impact factor: 2.643

Review 7.  B cells in multiple sclerosis.

Authors:  Mark P Burgoon; Donald H Gilden; Gregory P Owens
Journal:  Front Biosci       Date:  2004-01-01

8.  Increased detection of serum HHV-6 DNA sequences during multiple sclerosis (MS) exacerbations and correlation with parameters of MS disease progression.

Authors:  Rossana Berti; Meghan B Brennan; Samantha S Soldan; Joan M Ohayon; Luca Casareto; Henry F McFarland; Steven Jacobson
Journal:  J Neurovirol       Date:  2002-06       Impact factor: 2.643

Review 9.  Human Herpesviruses 6A and 6B in Brain Diseases: Association versus Causation.

Authors:  Anthony L Komaroff; Philip E Pellett; Steven Jacobson
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

Review 10.  Viruses and multiple sclerosis.

Authors:  Jussi Oskari Virtanen; Steve Jacobson
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-08       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.